Repinotan

Repinotan (BAYx3702) is a selective 5-HT1A receptor full agonist with high potency and efficacy. It has neuroprotective effects in animal studies,  and was trialled in humans for reducing brain injury following head trauma. It was subsequently trialled up to phase II for treatment of stroke, but while side effects were mild and consisted mainly of nausea, repinotan failed to demonstrate sufficient efficacy to justify further clinical trials. However repinotan continues to be investigated for other applications, and was found to be effective at counteracting the respiratory depression produced by morphine, though with slight reduction in analgesic effects.